Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Jun;16(2):87-92.
doi: 10.3904/kjim.2001.16.2.87.

The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus

S A Chang  1 , B Y Cha, S J Yoo, Y B Ahn, K H Song, J H Han, J M Lee, H S Son, K H Yoon, M I Kang, K W Lee, H Y Son, S K Kang
Affiliations
Comparative Study

The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus

S A Chang et al. Korean J Intern Med. 2001 Jun.

Abstract

Background: It has been reported that many peripheral vasodilating drugs might improve insulin resistance. Cilostazol, a antithrombotic agent, increases peripheral blood flow in non-insulin dependent diabetic patients. The effect of cilostazol treatment on insulin resistance in streptozotocin (STZ)-induced non-insulin dependent diabetic Wistar rats was examined.

Methods: About a half of two-day old neonate siblings were injected intraperitoneally with STZ and maintained for six months, at which time they were compared with age-matched control rats for intraperitoneal glucose tolerance test (IPGTT) and for glucose infusion rate (GINF) in a euglycemic hyperinsulinemic glucose-clamp study. After that, these studies were also performed after feeding rat chow containing cilostazol (100 mg/kg/day) to rats with STZ-induced non-insulin dependent diabetes mellitus for four-weeks and compared with those of age-matched control rats.

Results: In the intraperitoneal glucose tolerance test studies, plasma glucose levels of STZ-induced non-insulin dependent diabetic rats were significantly higher and plasma insulin levels significantly lower than those of age-matched control rats in the age of six months. Glucose infusion rate was lower in STZ-induced non-insulin dependent diabetic rats than those of age-matched control rats. However, after a four-week cilostazol treatment, glucose infusion rate of STZ-induced non-insulin dependent diabetic rats was not significantly different from that of control rats.

Conclusion: These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Plasma glucose (A) and insulin (B) concentrations in response to an intraperitoneal glucose challenge (2 g glucose/kg) in 6 month-old streptozotocin induced non-insulin dependent diabetic rats and normal control rats. Values presented as mean ± SEM.
Figure 2.
Figure 2.
Plasma glucose (A) and insulin (B) concentrations in response to an intraperitoneal glucose challenge (2g glucose/kg) in 7 month-old streptozotocin induced non-insulin dependent diabetic rats with 4 weeks of cilostazol treatment and their age-matched control rats. Values presented as mean ± SEM.
Figure 3.
Figure 3.
Fasting free fatty acid levels in normal control and streptozotocin induced non-insulin dependent diabetic rats before (6 months) and after (7 months) cilostazol treatment. Values presented as mean ± SEM.
Figure 4.
Figure 4.
Effects of cilostazol on glucose infusion rate in normal age-matched control and streptozotocin induced non-insulin dependent diabetic rats before (6 months) and after 4 weeks of cilostazol treatment (7 months). Values presented as mean ± SEM.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pollare T, Lithell H, Selinus I, Berne C. Application of prazocin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988;31:415–420. - PubMed
    1. Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin dependent diabetes mellitus. Eur J Clin Invest. 1987;17:448–454. - PubMed
    1. Nishi T, Tabusa F, Tanaka T, Shimizu T, Kanbe T, Kimura Y, Nakagawa K. Studies on 2-oxoquinolinone derivatives as blood platelet aggregation inhibitors. II.6-[3-(1-cyclohexyl-5-tetrazolyl)propoxyl]- 1,2-dihydro-2-oxoquinolinone and related compounds. Chem Pharmacol Bull. 1983;31:1151–1157. - PubMed
    1. Kamiya T, Sakaguchi S. Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in extremities. Arzneim-Forsch/Drug Res. 1985;35:1201–1203. - PubMed
    1. Okuda Y, Kimura Y, Yamashita K. Cilostazol. Cardivasc Drug Rev. 1993;11:451–465.

Publication types